Related Experiment Video
Updated: May 30, 2026
06:04
Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation
Published on: August 8, 2025
Transcatheter aortic valve implantation: Current status and future perspectives
Pablo Salinas1, Raul Moreno, Jose L Lopez-Sendon
1Pablo Salinas, Raul Moreno, Jose L Lopez-Sendon, Department of Interventional Cardiology, University Hospital La Paz, 28046, Madrid, Spain.
World Journal of Cardiology
|July 21, 2011
Summary
Transcatheter aortic valve implantation (TAVI) offers a viable treatment for severe aortic stenosis in inoperable patients. This minimally invasive procedure demonstrates high success rates and good long-term outcomes.
Area of Science:
- Cardiovascular Medicine
- Interventional Cardiology
- Medical Devices
Background:
- Severe aortic stenosis (AS) typically requires surgical aortic valve replacement (SAVR).
- Approximately one-third of AS patients are inoperable due to high surgical risk.
- Inoperable patients treated medically have a poor prognosis, with 50% mortality at 2 years.
Purpose of the Study:
- To review the current status of transcatheter aortic valve implantation (TAVI) for severe AS.
- To compare the Edwards SAPIEN and CoreValve Revalving systems.
- To discuss patient selection, procedural outcomes, complications, and future perspectives of TAVI.
Main Methods:
- Review of current literature on transcatheter aortic valve implantation (TAVI).
- Focus on two commercially available TAVI systems: Edwards SAPIEN and CoreValve.
- Analysis of data from clinical trials and studies on TAVI procedures and outcomes.
Main Results:
- TAVI has demonstrated robust results in severe AS, particularly in high-risk patients.
- Success rates exceeding 90% and 30-day mortality rates below 10% reported in transfemoral TAVI studies.
- Long-term studies indicate good hemodynamic performance of TAVI prostheses.
Conclusions:
- TAVI is an effective treatment option for inoperable patients with severe aortic stenosis.
- Ongoing research is evaluating TAVI's non-inferiority compared to conventional surgery in high-risk populations.
- TAVI represents a significant advancement in managing severe AS, offering improved clinical outcomes.
Related Concept Videos
01:25Aortic Regurgitation III: Medical Management
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
01:22Mitral Valve Prolapse II: Assessment and Management
IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular tachycardia.